Literature DB >> 7025146

Study of rimantadine in the USSR: a review of the literature.

D M Zlydnikov, O I Kubar, T P Kovaleva, L E Kamforin.   

Abstract

The results of basic-science and clinical studies performed in the USSR with the drug rimantadine are summarized. In the investigations cited, the therapeutic and prophylactic efficacy of rimantadine against infection with influenza virus was tested, and rimantadine was shown to be clinically efficacious and free of toxicity, both in studies with volunteers and in persons with natural disease during epidemics of influenza. Administration of 50 mg of the drug for 15-30 days was effective for prevention of influenza, and administration, early in the course of illness, of dosage of 150 mg per day for three to five days resulted in a favorable clinical response. The combination of immunization and chemoprophylaxis was shown to be highly effective for the prevention of influenza.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7025146     DOI: 10.1093/clinids/3.3.408

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  18 in total

1.  Safety and pharmacokinetics of rimantadine small-particle aerosol.

Authors:  R L Atmar; S B Greenberg; J M Quarles; S Z Wilson; B Tyler; S Feldman; R B Couch
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

2.  Genetic basis of resistance to rimantadine emerging during treatment of influenza virus infection.

Authors:  R B Belshe; M H Smith; C B Hall; R Betts; A J Hay
Journal:  J Virol       Date:  1988-05       Impact factor: 5.103

Review 3.  Phytotoxicity and Other Adverse Effects on the In Vitro Shoot Cultures Caused by Virus Elimination Treatments: Reasons and Solutions.

Authors:  Katalin Magyar-Tábori; Nóra Mendler-Drienyovszki; Alexandra Hanász; László Zsombik; Judit Dobránszki
Journal:  Plants (Basel)       Date:  2021-03-31

4.  Safety and prophylactic efficacy of low-dose rimantadine in adults during an influenza A epidemic.

Authors:  M T Brady; S D Sears; D L Pacini; R Samorodin; J DePamphilis; M Oakes; W Soo; M L Clements
Journal:  Antimicrob Agents Chemother       Date:  1990-09       Impact factor: 5.191

Review 5.  Antiviral therapy for influenza : a clinical and economic comparative review.

Authors:  Alexander C Schmidt
Journal:  Drugs       Date:  2004       Impact factor: 9.546

6.  Current status of amantadine and rimantadine as anti-influenza-A agents: memorandum from a WHO meeting.

Authors: 
Journal:  Bull World Health Organ       Date:  1985       Impact factor: 9.408

7.  Amantadine inhibits an early, M2 protein-dependent event in the replication cycle of avian influenza (H7) viruses.

Authors:  A P Kendal; H D Klenk
Journal:  Arch Virol       Date:  1991       Impact factor: 2.574

8.  Serum concentrations and safety of rimantadine in paediatric patients.

Authors:  M C Nahata; M T Brady
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 9.  Amantadine and rimantadine prophylaxis of influenza A in nursing homes. A tolerability perspective.

Authors:  D R Guay
Journal:  Drugs Aging       Date:  1994-07       Impact factor: 3.923

10.  Pharmacokinetics and metabolism of rimantadine hydrochloride in mice and dogs.

Authors:  H E Hoffman; J C Gaylord; J W Blasecki; L M Shalaby; C C Whitney
Journal:  Antimicrob Agents Chemother       Date:  1988-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.